IDRI offers services to other research organizations in two key areas:

Formulation development, drug manufacturing and fill & finish services in state-of-the-art labs and cGMP facilities. These include:

  • Formulation development services with a focus on liquid, emulsion and liposome formulations
  • cGMP drug product manufacturing for preclinical, Phase 1 and 2 clinical studies with a batch capacity of up to 15,000 vials of drug product in compliance with U.S. and EU regulations
  • Stability studies performed in compliance with ICH guidelines

High throughput, high content analysis (HCA) of host and pathogen interactions in BSL3 labs. These include:

  • High throughput drug screening of Mycobacterium tuberculosis-infected eukaryotic cells
  • Drug or vaccine formulation cytotoxic effects on eukaryotic cell viability
  • Drug or vaccine formulation effects on eukaryotic cell signaling cascades
  •  Assay development